- Home
- AMZE vs NCNA Comparison
AMZE vs NCNA Comparison
Compare AMZE & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZE | NCNA |
|---|---|---|
| Founded | 2019 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.6M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AMZE | NCNA |
|---|---|---|
| Price | $0.39 | $3.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 16.9M | 56.0K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,245,143.00 | N/A |
| Revenue This Year | $6,741.66 | N/A |
| Revenue Next Year | $100.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 369.95 | N/A |
| 52 Week Low | $0.24 | $2.78 |
| 52 Week High | $19.44 | $330.00 |
Technical Indicators
Market Signals| Indicator | AMZE | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 42.99 |
| Support Level | $0.35 | $3.30 |
| Resistance Level | $0.45 | $4.55 |
| Average True Range (ATR) | 0.06 | 0.27 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 48.69 | 22.40 |
Price Performance
Historical ComparisonAbout AMZE Amaze Holdings Inc.
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.